SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

• Jose Angel Garcia-Saenz ^[1] ; Isabel Blancas ^[2] ; Isabel Echavarria ^[3] ; Carmen Hinojo ^[4] ; Mireia Margeli ^[5] ; Fernando Moreno ^[1] ; Sonia Pernas ^[7] ; Teresa Ramon y Cajal ^[6] ; Nuria Ribelles ^[8] ; Meritxell Bellet ^[9]
  1. [1] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  2. [2] Hospital Universitario San Cecilio

     Hospital Universitario San Cecilio

     Granada, España

     
  3. [3] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  4. [4] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  5. [5] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  6. [6] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  7. [7] Institut Català d’Oncologia (ICO)-L’Hospitalet, Institut d’Investigacio Biomedica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, España
  8. [8] UGCI Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria (IBIMA), Málaga, España
  9. [9] Hospital Universitario Vall D’Hebron e Instituto de Oncología Vall d’Hebron (VHIO), Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 9 (September), 2023, págs. 2665-2678
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.